Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
Aged
Alleles
Biomarkers, Tumor
Disease Susceptibility
Female
Gene Expression
Genetic Heterogeneity
Genetic Predisposition to Disease
High-Throughput Nucleotide Sequencing
Humans
Immunoglobulin Heavy Chains
/ genetics
Immunohistochemistry
Immunophenotyping
Leukemia, Lymphocytic, Chronic, B-Cell
/ diagnosis
Male
Middle Aged
Mutation
clonal B-cell lymphocytosis
marginal zone lymphoma
next-generation sequencing
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
30
05
2020
revised:
20
07
2020
accepted:
23
07
2020
pubmed:
2
8
2020
medline:
12
1
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
Non-chronic lymphocytic leukemia (non-CLL) clonal B-cell lymphocytosis (CBL) encompasses a heterogeneous group of hematologic disorders that are still poorly understood. To shed light on their biological aspects, we retrospectively analyzed a highly selected series of 28 patients, who had a clonal B-cell population in the peripheral blood and in the bone marrow, without evidence of lymphoma. Extended targeted next-generation sequencing revealed wide molecular heterogeneity with MYD88 (14%), PDE4DIP (14%), BIRC3 (11%), CCND3 (11%), NOTCH1 (11%), and TNFAIP3 (11%) as the most mutated genes. Mutations of MYD88 were "nonclassic" in most cases. Although some genetic lesions were overlapping with indolent lymphomas, mainly splenic B-cell lymphomas of marginal zone origin and splenic diffuse red pulp small B-cell lymphoma, the genetic profile of our non-CLL CBL series seemed to suggest that various pathways could be involved in the pathogenesis of these disorders, not mirroring any specific lymphoma entity. These data better enlighten the molecular characteristics of non-CLL CBL; however, more efforts are needed in order to improve the diagnostic process, prognostication, and clinical management.
Substances chimiques
Biomarkers, Tumor
0
Immunoglobulin Heavy Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-697Subventions
Organisme : Italian Ministry of Education, University and Research (MIUR) to the Departments of Molecular Medicine (DMM) of the University of Pavia under the initiative "Dipartimenti di Eccellenza (2018-2022)"
Organisme : Fondazione Regionale Ricerca Biomedica (FRRB)
ID : 2015-0042
Organisme : "Ricerca Corrente Fondazione IRCCS Policlinico San Matteo" (P.I. Luca Arcaini)
Organisme : Ricerca Corrente Fondazione IRCCS Policlinico San Matteo (P.I. Luca Arcaini)
Informations de copyright
© 2020 John Wiley & Sons Ltd.